SCHEMBL7179643

SCHEMBL7179643

COc1cc(OC)c(C(=O)Pc2ccc(Oc3ccccc3)cc2Oc2ccccc2)c(OC)c1.[LiH]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.44
MEN1 O00255 3/20 0.44
TTR P02766 1/20 0.43
KDM4E B2RXH2 3/20 0.42
POLB P06746 1/20 0.42
LTA4H P09960 1/20 0.41
PGR P06401 1/20 0.41
CYP3A4 P08684 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
USP2 O75604 1/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 2/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
ATM Q13315 1/20 0.40
RAB9A P51151 1/20 0.40
ALDH1A1 P00352 2/20 0.39
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
XDH P47989 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7179648 0.97 KMT2A (0.44) KMT2AMEN1TTRKDM4EPOLB
SCHEMBL7190190 0.93 MEN1 (0.44) KMT2AMEN1TTRKDM4EPOLB
SCHEMBL7181462 0.90 KMT2A (0.41) KMT2AMEN1TTRKDM4EPOLB
Lithium SCHEMBL7190200 0.90 MEN1 (0.44) KMT2AMEN1TTRKDM4EPOLB
SCHEMBL7189149 0.86 KMT2A (0.41) KMT2AMEN1TTRKDM4EPOLB
SCHEMBL7190348 0.86 LTA4H (0.45) KMT2AMEN1TTRKDM4EPOLB
SCHEMBL7175847 0.85 TTR (0.45) KMT2AMEN1TTRKDM4EPOLB
SCHEMBL7188265 0.84 KMT2A (0.51) KMT2AMEN1CYP3A4SMN1; SMN2USP2
SCHEMBL7175874 0.84 MEN1 (0.44) KMT2AMEN1KDM4EPOLBSMN1; SMN2
Lithium SCHEMBL7189155 0.83 KMT2A (0.41) KMT2AMEN1TTRKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885MEN1 2312/4885TTR 2781/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885MEN1 2263/4885TTR 2797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.